Results 211 to 220 of about 1,491,011 (268)

Correction to 'FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study'. [PDF]

Liver Int
europepmc   +1 more source

Ototoxicity beyond platinum-based derivatives. [PDF]

Cancer Chemother Pharmacol
Peruch CV, Machado MS, Martins VB, de Oliveira Goulart F, Batista Berbert MC, Dallegrave E.   +5 more
europepmc   +1 more source

Multi‐Omics Profiling of High‐Grade Serous Ovarian Cancer Reveals an Inflammation‐Related Lipid Metabolism Subtype Associated With Platinum Resistance

Advanced Science, EarlyView.
Through integrated proteomic and metabolomic profiling, Zhao et al. identified three molecular subtypes of high‐grade serous ovarian cancer. The high‐risk subtype exhibits activated arachidonic acid metabolism and cyclooxygenase‐2 overexpression. This metabolic axis promotes M2‐like macrophage infiltration, which contributes to platinum resistance ...
Yuxi Zhao, Junyi Li, Bo Zheng, Wanshan Liu, Yaru Wang, Shufeng Wang, Ying Cui, Huiqin Guo, Hongxia Wang, Ting Xiao, Kun Qian, Jing Zuo   +11 more
wiley   +1 more source

Comparing chemotherapy-induced nausea and vomiting between young adult vs non-young adult cancer patients. [PDF]

JNCI Cancer Spectr
Oswald LB, Hoogland AI, Welniak TL, Nguyen OL, Rodriguez Y, Li X, Reese S, Lake PW, Gonzalez BD, Extermann M, Metts J, Murphy MA, Small BJ, Berry DL, Li D, Carpenter KM, Fischer SM, Kinney AY, Jim HSL.   +18 more
europepmc   +1 more source

TET1 Inhibition Promotes Therapeutic Sensitivity in TP53‐Mutant GBM by Influencing Genome Fragility and Altering TAMs Biology

Advanced Science, EarlyView.
In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu, Jinqiu Liu, Yuxuan Deng, Shuyu Hao, Xiaoli Zhang, Mingxu Yang, Chao Guo, Chao Du, Yingdan Chen, Tai Sun, Nan Ji, Zhengping Zhuang, Jie Feng   +12 more
wiley   +1 more source

Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results from the second randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial. [PDF]

EClinicalMedicine
Reni M, Orsi G, Carconi C, Malleo G, Procaccio L, Macchini M, Bencardino K, Merelli B, Pretta A, Rapposelli IG, Pecorelli N, Partelli S, Sperti E, Crippa S, Liscia N, Di Marco M, Milella M, Lonardi S, Palumbo D, Torri V, Falconi M.   +20 more
europepmc   +1 more source

CALB2 is a Mechanoresistance Gene in Metastatic Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer cell lines of differing origins were cultured over many passages while being subjected to semi‐lethal levels of fluid shear stress, representing the harsh mechanical environment these cells are subjected to in the circulation during the process of distant metastasis.
Abigail R. Fabiano, Allen C. Luo, Paul Taufalele, Jenna A. Dombroski, Ehsan Aalaei, Schyler J. Rowland, Melissa S. Cantú, Alexandria T. Carter, Samantha V. Knoblauch, Cynthia A. Reinhart‐King, Michael R. King   +10 more
wiley   +1 more source

Optimizing PD-1/PD-L1 inhibitors plus chemotherapy for driver mutation-negative non-squamous NSCLC in China: a cost-effectiveness analysis. [PDF]

Front Pharmacol
Ji J, Du Q, Teng M, Qin F, Zhang R, Dong Y.   +5 more
europepmc   +1 more source

Multi‐regional Organoid Biobank Reveals FAK‐ACSL1‐Driven Doxorubicin‐Resistance and Predictive Biomarkers in Breast Cancer

Advanced Science, EarlyView.
This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu, Zhijun Qin, Jiapeng Yang, Baoyuan Zhang, Manqing Cao, Peng Wang, Zaiqi Wang, Jinghui Cheng, Lei Wang, Hong Liu, Hui Yang   +10 more
wiley   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source